Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, Double-Blind, Drug Repositioning Clinical Trial comparative with placebo, to Evaluate the Efficacy and Safety of FDA-277 in Combination with Standard of Care in the Treatment of Infection Caused by SARS-CoV-2, in Patients With early Stage COVID-19 Disease, Receiving Primary Care Treatment.

    Summary
    EudraCT number
    2021-001228-17
    Trial protocol
    ES  
    Global end of trial date
    03 Nov 2022

    Results information
    Results version number
    v1(current)
    This version publication date
    06 Jan 2023
    First version publication date
    06 Jan 2023
    Other versions
    Summary report(s)
    Summary

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CSIC-FDA277-2021-01
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Agencia Estatal Consejo Superior de Investigaciones Científicas, M.P.
    Sponsor organisation address
    Calle Serrano, 117, Madrid, Spain, 28006
    Public contact
    Sponsor, Agencia Estatal Consejo Superior de Investigaciones Científicas, M.P., 34 918373112, ana.martinez@csic.es
    Scientific contact
    Sponsor, Agencia Estatal Consejo Superior de Investigaciones Científicas, M.P., 34 918373112, ana.martinez@csic.es
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    08 Nov 2022
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    03 Nov 2022
    Global end of trial reached?
    Yes
    Global end of trial date
    03 Nov 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective is to evaluate the efficacy of FDA-277 combined with standard of care on reducing the SARS-CoV-2 viral load.
    Protection of trial subjects
    All patients could be treated for symptoms due to SARS-CoV-2 infection as per standard of care recommendation: • In mild clinical conditions: o Acetaminophen 500 mg 1-4 times daily for control of fever and as an analgesic. o Non-steroidal anti-inflammatory drugs in the doses indicated as per their fact sheet. o Symptomatic treatment. o Adequate hydration. • In moderate clinical conditions: o Only in the case of suspected bacterial co-infection/superinfection antibiotic treatment will be introduced with: o Amoxicillin/Clavulanic Acid 875 mg/125 mg every 8 hours for 7 days. o Alternatively, levofloxacin 500 mg every 12 hours on the first day and 500 mg every 24 hours for 4 days [thereafter]. o Symptomatic treatment. o Adequate hydration. o BRONCHODILATORS: If required, they were preferably administered in pressurized cartridge with individual holding chamber (spacer), to avoid aerosol generation: salbutamol, 100 mcg/inhalation plus Ipratropium Bromide 20 mcg/inhalation: 2 inhalations every 4-6 hours; inhaled corticosteroids: only used in patients with bronchial asthma or COPD. o SYSTEMIC CORTICOSTEROIDS: Use in outpatients without the need for oxygen therapy is not recommended. Its use could be counterproductive in patients who do not require oxygen therapy. They were exclusively recommended at low doses in patients requiring oxygen therapy. o ANTITHROMBOTIC PROPHYLAXIS: Low molecular weight heparin at prophylactic doses for patients immobilized or with risk factors: Enoxaparin 4,000 IU (40 mg) subcutaneously once daily. If creatinine clearance is observed at 15-30 mL/min, enoxaparin 2000 IU (20 mg) could be administered subcutaneously once daily. Enoxaparin was not recommended if creatinine clearance was less than 15 mL/min. Bemiparin could be used as an alternative. In all cases, home isolation was required, according to the rules applicable at the time of study
    Background therapy
    Standard of care
    Evidence for comparator
    Standard of care
    Actual start date of recruitment
    23 Mar 2022
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 173
    Worldwide total number of subjects
    173
    EEA total number of subjects
    173
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    146
    From 65 to 84 years
    27
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The first patient was included in the study on March 23, 2022. The last patient was included on October 6, 2022. The last patient last visit was completed on November 3, 2022.

    Pre-assignment
    Screening details
    The patients must be diagnosed of active SARS-CoV-2 infection confirmed by compatible symptoms and a positive result in the detection tests for active infection (DTAI), rapid antigen detection test or in the PCR for viral RNA detection test.

    Period 1
    Period 1 title
    Treatment and Follow-up period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst
    Blinding implementation details
    Allocation ratio 1:1 of study groups Domperidone plus SOC versus placebo plus SOC group. The random allocation sequence was generated by an independent technician, in random blocks of 4 and 6 treatments to distribute 10 randomization number envelopes by centre.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Domperidone
    Arm description
    Domperidone 3 daily doses of 10 mg (30 mg/day) for 7 days
    Arm type
    Experimental

    Investigational medicinal product name
    Domperidone
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Domperidone 3 daily doses of 10 mg (30 mg/day) for 7 days

    Arm title
    Placebo
    Arm description
    Matching Placebo 3 daily doses for 7 days
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    3 daily doses of matching placebo for 7 days

    Number of subjects in period 1
    Domperidone Placebo
    Started
    87
    86
    Completed
    83
    82
    Not completed
    4
    4
         Consent withdrawn by subject
    -
    2
         Adverse event, non-fatal
    2
    -
         Lost to follow-up
    2
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Treatment and Follow-up period
    Reporting group description
    This analysis population consist of all patients included in the “all randomized patient population” who have not violated the protocol so that it may affect the assessment of the effect of the study drug on the primary endpoint, ie, without major protocol deviations. The criteria for identifying major protocol deviations were reviewed prior to the start of the analysis and unblinding of treatment and was described in the analysis plan. 180 patients were randomized. Seven patients were excluded from the data set due to protocol deviation (placebo group 4; domperidone gropu 3). The set population was 173 patients.

    Reporting group values
    Treatment and Follow-up period Total
    Number of subjects
    173 173
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    146 146
        From 65-84 years
    27 27
        85 years and over
    0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    47.8 ± 15.2 -
    Gender categorical
    Units: Subjects
        Female
    109 109
        Male
    64 64
    SARS-CoV-2 infection severity
    Severity of SARS-CoV-2 infection at baseline
    Units: Subjects
        Asymptomatic
    3 3
        Mild disease
    166 166
        Moderate disease
    4 4
    SARS-CoV-2 complete vaccination
    Units: Subjects
        No
    14 14
        Yes
    159 159
    SARS-CoV-2 infection before the study
    Presence or absence of previous SARS-CoV-2 infection before the one for the selection for the study
    Units: Subjects
        No
    146 146
        Yes
    27 27
    Systolic Blood Pressure
    Units: mmHg
        arithmetic mean (standard deviation)
    124.6 ± 13.2 -
    Diastolic Blood Pressure
    Units: mmHg
        arithmetic mean (standard deviation)
    76.7 ± 9.9 -
    Respiratory rate
    Units: Inspirations/minute
        arithmetic mean (standard deviation)
    15.9 ± 5.5 -
    Oxygen saturation
    Units: Saturation %
        arithmetic mean (standard deviation)
    97.2 ± 0.1 -
    Heart rate
    Units: Pulses/minute
        arithmetic mean (standard deviation)
    81.8 ± 1 -
    Temperature
    Axillary temperature
    Units: ºC
        arithmetic mean (standard deviation)
    36.4 ± 0.1 -
    Time from previous SARS-CoV-2 infection
    Units: Months
        arithmetic mean (standard deviation)
    14.2 ± 1.7 -
    Time from last SRS-CoV-2 vaccination dose
    Units: Month
        arithmetic mean (standard deviation)
    6.3 ± 0.3 -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Domperidone
    Reporting group description
    Domperidone 3 daily doses of 10 mg (30 mg/day) for 7 days

    Reporting group title
    Placebo
    Reporting group description
    Matching Placebo 3 daily doses for 7 days

    Primary: Change in ORF1ab viral load (Ct) Day4-Baseline

    Close Top of page
    End point title
    Change in ORF1ab viral load (Ct) Day4-Baseline
    End point description
    Baseline – 4 days difference ORF1ab RT-PCR number of cycles. The viral load was estimated by the number of cycles (Cts) until detection of three specific genes of the SARS-Cov-2 pathogenic viral strain, using the TaqPath COVID-19 CE-IVD RT-PCR Kit (Thermofisher, USA), which detects three highly conserved regions of the RNA SARS-CoV-2 virus along with an internal positive control (MS2-IPC) in a single PCR reaction: genes encoding ORF1ab, N Protein, S Protein, with a sensitivity of >99% and Specificity of 99.5%. For the correct interpretation of data: an increase in the number of amplified cycles means a better result as a reduction in the viral load. So, the difference D4-D0 positive means an improvement, better as the figure is higher. If the difference D4-D0 is negative, it means a worsening.
    End point type
    Primary
    End point timeframe
    Baseline - Day 4 of treatment
    End point values
    Domperidone Placebo
    Number of subjects analysed
    87
    86
    Units: Number of RT-PCR cycles
        arithmetic mean (standard error)
    5.7 ± 0.5
    6.1 ± 0.5
    Attachments
    Untitled (Filename: ORF1ab_Baseline_Day4.pdf)
    Statistical analysis title
    Student t test for independent groups
    Statistical analysis description
    Student t test for independent groups
    Comparison groups
    Domperidone v Placebo
    Number of subjects included in analysis
    173
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.551
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.01
         upper limit
    1.9
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.7

    Primary: Change in N Protein viral load (Ct) Day4-Baseline

    Close Top of page
    End point title
    Change in N Protein viral load (Ct) Day4-Baseline
    End point description
    Baseline – 4 days difference ORF1ab RT-PCR number of cycles. The viral load was estimated by the number of cycles (Cts) until detection of three specific genes of the SARS-Cov-2 pathogenic viral strain, using the TaqPath COVID-19 CE-IVD RT-PCR Kit (Thermofisher, USA), which detects three highly conserved regions of the RNA SARS-CoV-2 virus along with an internal positive control (MS2-IPC) in a single PCR reaction: genes encoding ORF1ab, N Protein, S Protein, with a sensitivity of >99% and Specificity of 99.5%. For the correct interpretation of data: an increase in the number of amplified cycles means a better result as a reduction in the viral load. So, the difference D4-D0 positive means an improvement, better as the figure is higher. If the difference D4-D0 is negative, it means a worsening.
    End point type
    Primary
    End point timeframe
    Baseline - Day 4 of treatment
    End point values
    Domperidone Placebo
    Number of subjects analysed
    87
    86
    Units: Number of RT-PCR cycles
        arithmetic mean (standard error)
    5.6 ± 0.5
    6 ± 0.5
    Attachments
    Untitled (Filename: NProtein_Baseline_Day4.pdf)
    Statistical analysis title
    Student t test for independent groups
    Comparison groups
    Domperidone v Placebo
    Number of subjects included in analysis
    173
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.505
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.5
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.9
         upper limit
    1.8
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.7

    Primary: Change in S Protein viral load (Ct) Day4-Baseline

    Close Top of page
    End point title
    Change in S Protein viral load (Ct) Day4-Baseline
    End point description
    Baseline – 4 days difference ORF1ab RT-PCR number of cycles. The viral load was estimated by the number of cycles (Cts) until detection of three specific genes of the SARS-Cov-2 pathogenic viral strain, using the TaqPath COVID-19 CE-IVD RT-PCR Kit (Thermofisher, USA), which detects three highly conserved regions of the RNA SARS-CoV-2 virus along with an internal positive control (MS2-IPC) in a single PCR reaction: genes encoding ORF1ab, N Protein, S Protein, with a sensitivity of >99% and Specificity of 99.5%. For the correct interpretation of data: an increase in the number of amplified cycles means a better result as a reduction in the viral load. So, the difference D4-D0 positive means an improvement, better as the figure is higher. If the difference D4-D0 is negative, it means a worsening.
    End point type
    Primary
    End point timeframe
    Baseline - Day 4 of treatment
    End point values
    Domperidone Placebo
    Number of subjects analysed
    87
    86
    Units: Number of RT-PCR cycles
        arithmetic mean (standard error)
    3.6 ± 0.5
    3.7 ± 0.6
    Attachments
    Untitled (Filename: SProtein_Baseline_Day4.pdf)
    Statistical analysis title
    Student t test for independent groups
    Comparison groups
    Domperidone v Placebo
    Number of subjects included in analysis
    173
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.981
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.5
         upper limit
    1.5
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.8

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Timeframe from Day 1 to Day 28
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    25.0
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Placebo

    Reporting group title
    Domperidone
    Reporting group description
    Domperidone 3 daily doses of 10 mg (30 mg/day) for 7 days

    Serious adverse events
    Placebo Domperidone
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 86 (0.00%)
    0 / 87 (0.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Placebo Domperidone
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    9 / 86 (10.47%)
    14 / 87 (16.09%)
    Investigations
    Oxygen saturation decreased
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Injury, poisoning and procedural complications
    Traumatic fracture
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Vascular disorders
    Hypertension
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    1
    0
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    0 / 86 (0.00%)
    2 / 87 (2.30%)
         occurrences all number
    0
    2
    Presyncope
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    1
    0
    Tachycardia
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    1
    0
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    1
    0
    Paresthesia
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    1
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    1
    0
    Eye disorders
    Vision blurred
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal disorders
    Abdominal discomfort
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Abdominal pain
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Abdominal pain upper
         subjects affected / exposed
    1 / 86 (1.16%)
    1 / 87 (1.15%)
         occurrences all number
    1
    1
    Dyspepsia
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Nausea
         subjects affected / exposed
    2 / 86 (2.33%)
    0 / 87 (0.00%)
         occurrences all number
    2
    0
    Tongue pruritus
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    0
    0
    Vomiting
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Reproductive system and breast disorders
    Menometrorrhagia
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Hepatobiliary disorders
    Cholelithiasis
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Urticaria
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    1
    0
    Infections and infestations
    Bacterial infection
         subjects affected / exposed
    0 / 86 (0.00%)
    1 / 87 (1.15%)
         occurrences all number
    0
    1
    Herpes simplex
         subjects affected / exposed
    1 / 86 (1.16%)
    0 / 87 (0.00%)
         occurrences all number
    1
    0
    Vulvovaginitis
         subjects affected / exposed
    0 / 86 (0.00%)
    2 / 87 (2.30%)
         occurrences all number
    0
    2

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA